Massive Real-World study tracks diabetes Drug's dual benefits

NCT ID NCT05970237

Recruiting now Knowledge-focused Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will follow 9,000 people with type 2 diabetes and high blood pressure who are already taking dapagliflozin. Researchers want to see how well the drug controls blood sugar and blood pressure in real-life settings. It is an observational study, meaning no new treatment is given—just careful tracking of outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If successful, this study could provide real-world evidence on how well dapagliflozin controls blood sugar and blood pressure in everyday patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only observes existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS HYPERTENSION

Contacts and locations

Locations

Gachon University Gil Medical Center
RECRUITING

Incheon, Namdong-gu, 21565, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.